USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Acumen Pharmaceuticals, Inc.
Address:
Acumen Pharmaceuticals, Inc.
385 Oyster Point Blvd.
South San Francisco, CA 94080
Phone:
(650) 875-7700
URL:
N/A
EIN:
364108129
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $329,524.00 2

Award List:

Drug discovery of anti-ADDL therapeutics for Alzheimer's

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$183,750.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Recent evidence suggests that the primary cause of Alzheimer's disease is the progressive accumulation of neurotpxic oligomeric assemblies of the Abeta 1-42 protein. These neurotoxic oligomeric species are known as ADDLs (Ab-derived diffusible ligands). In… More

Biomarker for Alzheimer's Related Cognitive Deficits

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$145,774.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The molecular and cellular details underlying Alzheimer's disease (AD) are being defined at an accelerating pace, leading to new therapeutic discovery efforts that target reduction of A-beta or ADDLs (A-beta-derived diffusible ligands), the neurotoxic oligomeric… More